Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma

Area of Science:

• Oncology
• Epigenetics
• Hepatocellular Carcinoma Research

Background:

• Epigenetic therapies, including histone deacetylase inhibitors (HDAC-I) and demethylating agents (DA), are emerging as innovative treatments.
• Histone deacetylase inhibitors (HDAC-I) have demonstrated significant therapeutic potential against hepatocellular carcinoma (HCC).
• This study investigates a combined HDAC-I/DA epigenetic regimen for chemotherapy-resistant HCC.

Purpose of the Study:

• To evaluate the preclinical efficacy of a combined HDAC-I and DA epigenetic regimen in hepatocellular carcinoma (HCC).
• To assess the safety and antitumor effects of this combination therapy in HCC models.

Main Methods:

• Human HCC cell lines and primary human hepatocytes (PHH) were treated with suberoylanilide hydroxamic acid (SAHA, an HDAC-I) and 5-aza-2'-deoxycytidine (5-aza-dC, a DA), alone and in combination.
• Evaluated endpoints included cellular damage, proliferation, histone acetylation, and DNA methylation.
• In vivo efficacy was assessed using a xenograft hepatoma model.

Main Results:

• Combined SAHA and 5-aza-dC treatment significantly enhanced antiproliferative effects in HCC cells compared to monotherapy.
• The combination regimen showed dose-dependent cellular damage in HCC cell lines but not in primary human hepatocytes (PHH).
• In vivo studies demonstrated statistically significant inhibition of hepatoma cell growth with the combined treatment.

Conclusions:

• The combined HDAC-I/DA epigenetic approach exhibits significant antitumor effects in HCC models.
• This combination therapy demonstrated safety in untransformed hepatocytes, preserving cellular integrity.
• The promising preclinical results support further investigation of this combination therapy in clinical trials for HCC.